



Company Overview

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as graft-vs-host disease (GvHD) and NASH.

CytoDyn Announces FDA Has Lifted Clinical Hold

Feb 29 2024, 8:30 AM EST

CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma

Feb 1 2024, 8:30 AM EST

CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO

Jan 29 2024, 8:30 AM EST

Stock Overview

Symbol	CYDY
Exchange	OTCQB
Market Cap	144.97m
Last Price	\$0.14
52-Week Range	\$0.12 - \$0.41

04/16/2024 03:53 PM EDT

Management Team

Dr. Jacob Lalezari

CEO

Mitch Cohen

Interim CFO

Cyrus Arman, PhD, MBA

SVP, Business Operations

Scott Hansen, PhD

Head of Research & Basic Science

Bernie Cunningham, PhD, MRPharmS, PMP

Vice President of Operations

Joseph Meidling

Executive Director, Clinical Operations

Tyler Blok

Executive Vice President of Legal Affairs

CytoDyn Inc.

1111 Main Street
Suite 660
Vancouver, WA 98660

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.